Nanjing Leads Biolabs Co., Ltd. Class H(HK:9887)
HK$32.20-1.06 (-3.19%)
HK:9887
Nanjing Leads Biolabs Co., Ltd. Class H financials statements
HK$32.20
At close:-1.06 (-3.19%)
Want to see HK:9887 full AI Analyst Report?
Nanjing Leads Biolabs Co., Ltd. Class H (9887) Ratios
4 Followers
Nanjing Leads Biolabs Co., Ltd. Class H Ratios
HK:9887's free cash flow for Q2 2026 was ¥0.00. For the 2026 fiscal year, HK:9887's free cash flow was increased by ¥0.00 and operating cash flow was ¥0.00. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 |
|---|---|---|---|---|
| Liquidity Ratios | ||||
| Current Ratio | 3.37 | 1.50 | 0.26 | 0.44 |
| Quick Ratio | 3.25 | 1.50 | 0.26 | 0.44 |
| Cash Ratio | 2.43 | 0.94 | 0.18 | 0.21 |
| Solvency Ratio | -0.42 | -0.10 | -0.27 | -0.22 |
| Operating Cash Flow Ratio | -0.31 | -0.30 | -0.14 | -0.04 |
| Short-Term Operating Cash Flow Coverage | -0.59 | -0.47 | -3.16 | -0.04 |
| Net Current Asset Value | ¥ 1.17B | ¥ 192.42M | ¥ -1.03B | ¥ -681.75M |
| Leverage Ratios | ||||
| Debt-to-Assets Ratio | 0.16 | 0.40 | 0.15 | 1.93 |
| Debt-to-Equity Ratio | 0.22 | 1.00 | -0.07 | -1.98 |
| Debt-to-Capital Ratio | 0.18 | 0.50 | -0.08 | 2.02 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.41 | 2.52 | -0.47 | -1.03 |
| Debt Service Coverage Ratio | -0.80 | -0.14 | -4.29 | -0.17 |
| Interest Coverage Ratio | -30.91 | -6.91 | -206.45 | -704.00 |
| Debt to Market Cap | 0.03 | 0.03 | 0.01 | 0.11 |
| Interest Debt Per Share | 1.65 | 1.81 | 0.47 | 6.29 |
| Net Debt to EBITDA | 4.82 | 2.88 | 0.67 | -4.79 |
| Profitability Margins | ||||
| Gross Profit Margin | 100.00% | 0.00% | 64.07% | 0.00% |
| EBIT Margin | -109.75% | 0.00% | -2969.26% | 0.00% |
| EBITDA Margin | -98.99% | 0.00% | -2746.59% | 0.00% |
| Operating Profit Margin | -109.75% | 0.00% | -2969.26% | 0.00% |
| Pretax Profit Margin | -110.51% | 0.00% | -4086.28% | 0.00% |
| Net Profit Margin | -119.27% | 0.00% | -4086.28% | 0.00% |
| Continuous Operations Profit Margin | -119.27% | 0.00% | -4086.28% | 0.00% |
| Net Income Per EBT | 107.93% | 100.00% | 100.00% | 100.00% |
| EBT Per EBIT | 100.70% | 110.18% | 137.62% | 134.29% |
| Return on Assets (ROA) | -13.20% | -6.56% | -89.08% | -46.60% |
| Return on Equity (ROE) | -18.58% | -16.53% | 42.01% | 47.96% |
| Return on Capital Employed (ROCE) | -16.92% | -14.70% | 30.58% | 35.96% |
| Return on Invested Capital (ROIC) | -14.00% | -7.49% | 32.85% | -36.33% |
| Return on Tangible Assets | -13.22% | -6.56% | -89.08% | -46.60% |
| Earnings Yield | -2.95% | -0.46% | -4.53% | -2.57% |
| Efficiency Ratios | ||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 0.00 | 0.00 | 16.30 | 117.12 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 4.02 | 0.00 | 0.16 | 0.00 |
| Asset Turnover | 0.11 | 0.00 | 0.02 | 0.00 |
| Working Capital Turnover Ratio | 0.28 | 0.00 | -0.01 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -22.39 | -3.12 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 22.39 | 3.12 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | ||||
| Operating Cash Flow Per Share | -0.89 | -0.79 | -1.33 | -0.24 |
| Free Cash Flow Per Share | -0.95 | -0.81 | -1.41 | -0.39 |
| Dividend Paid and CapEx Coverage Ratio | -14.82 | -39.94 | -16.43 | -1.50 |
| Capital Expenditure Coverage Ratio | -14.82 | -39.94 | -16.43 | -1.50 |
| Operating Cash Flow Coverage Ratio | -0.55 | -0.45 | -2.87 | -0.04 |
| Operating Cash Flow to Sales Ratio | -0.78 | 0.00 | -19.75 | 0.00 |
| Free Cash Flow Yield | -2.07% | -1.29% | -2.32% | -0.67% |
| Valuation Ratios | ||||
| Price-to-Earnings (P/E) Ratio | -33.93 | -215.35 | -22.09 | -38.96 |
| Price-to-Sales (P/S) Ratio | 40.45 | 0.00 | 902.83 | 0.00 |
| Price-to-Book (P/B) Ratio | 6.30 | 35.60 | -9.28 | -18.68 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -48.39 | -77.62 | -43.08 | -150.22 |
| Price-to-Operating Cash Flow Ratio | -51.66 | -79.56 | -45.71 | -250.36 |
| Price-to-Earnings Growth (PEG) Ratio | -0.09 | 2.41 | -0.27 | 0.00 |
| Enterprise Value Multiple | -36.05 | -253.38 | -32.20 | -61.85 |
| Enterprise Value | 7.04B | 9.35B | 8.63B | 12.11B |
| EV to EBITDA | -36.05 | -253.38 | -32.20 | -61.85 |
| EV to Sales | 35.68 | 0.00 | 884.33 | 0.00 |
| EV to Free Cash Flow | -42.69 | -76.75 | -42.20 | -162.82 |
| EV to Operating Cash Flow | -45.57 | -78.67 | -44.77 | -271.35 |
| Tangible Book Value Per Share | 7.26 | 1.77 | -6.55 | -3.17 |
| Shareholders’ Equity Per Share | 7.27 | 1.77 | -6.55 | -3.17 |
| Tax and Other Ratios | ||||
| Effective Tax Rate | -0.08 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 1.13 | 0.00 | 0.07 | 0.00 |
| Net Income Per Share | -1.35 | -0.29 | -2.75 | -1.52 |
| Tax Burden | 1.08 | 1.00 | 1.00 | 1.00 |
| Interest Burden | 1.01 | 1.10 | 1.38 | 1.34 |
| Research & Development to Revenue | 1.63 | 0.00 | 26.04 | 0.00 |
| SG&A to Revenue | 0.47 | 0.00 | 4.29 | 0.00 |
| Stock-Based Compensation to Revenue | 0.05 | 0.00 | 1.83 | 0.00 |
| Income Quality | 0.79 | 0.39 | 0.53 | 0.16 |
Currency in CNY

